Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetes AND Lantus (Insulin glargine) AND Insulin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    168 result(s) found for: Diabetes AND Lantus (Insulin glargine) AND Insulin. Displaying page 2 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2011-001209-28 Sponsor Protocol Number: RXQ425 Start Date*: 2011-07-21
    Sponsor Name:Buckinghamshire Healthcare NHS Trust
    Full Title: Impact of insulin detemir versus insulin glargine on glycaemic control and metabolism during exercise in Type 1 diabetes
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003219-20 Sponsor Protocol Number: NN9535-4386 Start Date*: 2018-09-13
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes A 52-week, multi-ce...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SI (Completed) EE (Completed) BG (Completed) LV (Completed) PL (Completed) GR (Completed) DE (Completed) CZ (Completed) LT (Completed) PT (Completed) ES (Completed) HR (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-001524-35 Sponsor Protocol Number: EFC12456 Start Date*: 2012-10-12
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Pat...
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) FI (Completed) CZ (Completed) LV (Completed) HU (Completed) NL (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000828-15 Sponsor Protocol Number: I4L-MC-ABEC Start Date*: 2011-09-08
    Sponsor Name:Eli Lilly and Company
    Full Title: A Prospective, Randomized, Double-Blind Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Patients with Type 2 Diabetes Mellitus
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) GR (Completed) PL (Completed) HU (Completed) DE (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007335-40 Sponsor Protocol Number: EFC10781 Start Date*: 2009-10-01
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of lixisenatide in patients with Type 2 dia...
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    11.1 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) EE (Completed) NL (Completed) CZ (Completed) HU (Completed) DK (Completed) IT (Completed) PL (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000747-32 Sponsor Protocol Number: MYL-GAI-3001 Start Date*: 2014-08-27
    Sponsor Name:MYLAN GmbH
    Full Title: AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL-GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN’S INSULIN GLARGINE WITH LANTUS® IN TYPE 1 DIABETES MELLITUS PATIENTS
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) DE (Completed) GB (Completed) EE (Completed) HU (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2004-002036-25 Sponsor Protocol Number: HMR1964A/3506 Start Date*: 2005-01-27
    Sponsor Name:sanofi aventis groupe
    Full Title: Comparison of three therapeutic strategies for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drugs.
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) IT (Completed) SE (Completed) ES (Completed) LT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-011231-12 Sponsor Protocol Number: EFC11202 Start Date*: 2009-11-11
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A 24-week, randomized, open-label, parallel group multinational comparison of Lantus® (insulin glargine) given in the morning as once-a-day basal insulin versus Neutral Protamine Hagedorn (NPH) ins...
    Medical condition: Patients with type 1 diabetes mellitus, aged at least 1 year to less than 6 years
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012609 LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) DE (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-002047-92 Sponsor Protocol Number: Birdsong Start Date*: 2007-01-31
    Sponsor Name:Newcastle Primary Care Trust
    Full Title: A multicentre, open-label, randomized comparison of once daily insulin detemir given pre-breakfast or bedtime, according to need, with bedtime insulin glargine in people with type 2 diabetes charac...
    Medical condition: Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005174-56 Sponsor Protocol Number: 12R-MC-BIDD Start Date*: 2014-05-30
    Sponsor Name:Eli Lilly and Company
    Full Title: A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study: The IMAGIN...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004392-12 Sponsor Protocol Number: NN9535-3625 Start Date*: 2014-04-28
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) SK (Completed) DE (Completed) GB (Completed) NL (Completed) RO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004768-12 Sponsor Protocol Number: NN5401-4266 Start Date*: 2016-08-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 38 week trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without o...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-000476-38 Sponsor Protocol Number: NN1436-4481 Start Date*: 2021-03-01
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effectiveness and safety of once weekly insulin icodec used with DoseGuide versus once daily basal insulin analogues in an insulin naïve type 2 diabetes population in a clinical practice setting
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005777-35 Sponsor Protocol Number: NN1250-3582 Start Date*: 2009-08-05
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 52-week randomised, controlled, open label,multicentre, multinational treat-to target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a basal-bolu...
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) ES (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-001596-48 Sponsor Protocol Number: NN9068-4229 Start Date*: 2016-03-29
    Sponsor Name:Novo Nordisk A/S
    Full Title: A clinical trial comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FI (Completed) HU (Completed) ES (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-015742-34 Sponsor Protocol Number: APIDR_L_04717 Start Date*: 2009-12-11
    Sponsor Name:sanofi-aventis
    Full Title: Better Accepance of a Singe injection Apidra (insulin glulisine) Added to once daily Lantus (insulin glargine) versus twice daily Premixed insulin in a real Life Use Setting.
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006599-39 Sponsor Protocol Number: VIAject™-06J Start Date*: 2007-08-28
    Sponsor Name:BIODEL Inc.
    Full Title: An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT™ and Regular Human Insulin in Patients with Type 1 Diabetes Mellitus
    Medical condition: Diabetes Mellitus Type 1
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004639-38 Sponsor Protocol Number: APIDR_L_04884 Start Date*: 2015-04-03
    Sponsor Name:Sanofi
    Full Title: A study of effectiveness and safety of Apidra in combination with Lantus therapy in basal-bolus insulin regimen in inadequately controlled children and adolescents with Type 1 diabetes in the Russi...
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-011399-31 Sponsor Protocol Number: NN1250-3718 Start Date*: 2009-12-21
    Sponsor Name:Novo Nordisk A/S
    Full Title: BEGIN™: EASY PM A trial comparing the efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) FR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-001855-23 Sponsor Protocol Number: BC20965 Start Date*: 2009-04-14
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multi-center, randomized, open-label, active-controlled study to compare the efficacy, safety and tolerability of taspoglutide (RO5073031) versus insulin glargine in insulin-naive type 2 diabetic...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Completed) DE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) PT (Completed) GB (Prematurely Ended) IT (Prematurely Ended) BE (Completed) FI (Completed) GR (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Oct 30 21:11:00 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA